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Abstract
Objectives—To describe neurodevelopmental outcomes in infants with single ventricle (SV)
physiology and determine factors associated with worse outcomes.
Study design—Neurodevelopmental outcomes for infants with SV enrolled in a multicenter
drug trial were assessed at 14 months of age using the Bayley Scales of Infant Development-II.
Multivariable regression analysis was used to identify factors associated with worse outcomes.
Results—Neurodevelopmental testing was performed at 14±1 months in 170/185 subjects in the
trial. Hypoplastic left heart syndrome was present in 59% and 75% had undergone the Norwood
operation. Mean psychomotor (PDI) and mental developmental indices (MDI) were 80±18 and
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96±14 respectively (normal 100±15, P<0.001 for each). Group-based trajectory analysis provided
a two-group model (high” and “low”) for height z-score trajectory and brain type natriuretic
peptide (BNP) trajectory. The predicted PDI scores were 15 points higher in the “high” height zscore trajectory compared with the “low” cluster (P<.001). A higher number of serious adverse
events during the trial was associated with lower PDI scores (P=.02). The predicted MDI scores
were 13–17 points lower in “low height trajectory- high BNP trajectory” group compared with the
other three groups (P<.001). MDI scores were also lower in subjects who required extracorporeal
membrane oxygenation during the neonatal hospitalization (P=.01) or supplemental oxygen at
discharge (P=.01).
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Conclusions—Neurodevelopmental outcome at 14 months of age is impaired in infants with SV
physiology. Low height trajectory and high BNP trajectory were associated with worse
neurodevelopmental outcomes. Efforts to improve nutritional status alone may not improve
neurodevelopmental outcomes.
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Academic difficulties, behavioral problems, motor impairment, speech delays, inattention
and hyperactivity are common in survivors of cardiac surgery in infancy, with the greatest
risk in children with single ventricle (SV) physiology [1]. The etiology of
neurodevelopmental disability is likely multifactorial with the precise role of specific
medical, surgical, and socio-demographic factors not fully delineated [2–3]. Previous
investigators have focused on peri-operative events as important etiologic factors [4–6].
Growth failure during early infancy has been implicated in impaired development of
executive function and worse school performance in children without congenital heart
defects (CHD) [7–9]. In other “at risk” populations such as extreme prematurity, catch-up
growth in weight and head circumference from birth to hospital discharge has been
associated with better neurocognitive outcome at 5 years (10). Poor growth occurs
frequently in infants with SV physiology particularly prior to performance of the superior
cavopulmonary connection (SCPC) [11–16]. Despite this, the impact of poor growth on
neurodevelopmental outcome in infants with SV has not been studied.
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As part of the Infant Single Ventricle (ISV) trial, survivors underwent neurodevelopmental
testing at 14 months and growth was measured longitudinally from enrollment. Using groupbased trajectory modeling to characterize growth patterns during infancy, we sought to
evaluate the impact of growth pattern on neurodevelopmental outcome [18]. Our hypothesis
was that lower trajectory of weight, height, and head circumference z-scores would be
associated with worse neurodevelopmental outcome. We also explored the association
between neurodevelopmental outcomes and patient characteristics, peri-operative course
during neonatal and second stage surgeries, ventricular function by echocardiography, and
measures of heart failure including serum brain type natriuretic peptide (BNP) concentration
and Ross classification.

Methods
The ISV trial conducted by the Pediatric Heart Network (PHN) was a randomized, doubleblind, placebo-controlled trial designed to determine whether enalapril improved growth and
ventricular function in infants with SV physiology [14]. 230 subjects were enrolled in 10
centers in North America between August 2003 and May 2007. The study protocol was
approved by the Institutional Review Board or Institutional Ethics Board at each
participating center, and written informed consent was obtained from parents prior to trial
enrollment. This clinical trial is registered at www.clinicaltrials.gov (NCT00113087).
Infants between one week and 45 days of age with SV physiology with stable systemic and
pulmonary blood flow in whom a SCPC was planned were eligible for participation in the
trial. Exclusion criteria included prematurity (gestational age less than 35 weeks), small for
J Pediatr. Author manuscript; available in PMC 2014 February 01.
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gestational age (birth weight less than 10th percentile for gestational age), and presence of
chromosomal or phenotypic syndromes known to be associated with growth failure [19].
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Neurodevelopmental testing with the BSID-II was performed at 14±1 months at the PHN
sites by a designated PHN site psychologist certified by the Data Coordinating Center’s
neuropsychological testing consultant (DCB). The BSID-II was administered in English or
Spanish depending on the dominant language spoken at home. The BSID-II provides two
scores: the Psychomotor Developmental Index (PDI), which assesses gross motor and fine
motor skills, and the Mental Developmental Index (MDI), which measures cognitive
functioning through assessment of memory, problem solving, number concepts,
vocalization, language and social interaction skills. The mean PDI and MDI score for the
normal population is 100, with a standard deviation (SD) of 15, and a minimal score of 50.
Subjects who were too impaired to complete neurodevelopmental testing were assigned a
score of 50.
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Patient characteristics, medical and surgical data were prospectively collected during the
neonatal and SCPC hospitalizations, and patients were followed until the age of 14 months.
Data collected included patient demographics, socioeconomic status (SES), details of
anatomic diagnosis, type of neonatal surgery, intra-operative support times during neonatal
surgery, post-operative duration of mechanical ventilation, hospital length of stay (LOS),
type and mode of feeding at hospital discharge, and use of supplemental oxygen at hospital
discharge, and adverse events from enrollment until the age of 14 months such as neurologic
events and use of extracorporeal membrane oxygenation (ECMO) (Appendix 2; available at
www.jpeds.com). Measurement of serum BNP concentration, Ross heart failure
classification (class 1–4), and assessment of ventricular size and function by
echocardiography was performed before the SCPC and at the 14 month visit [18]. BNP
concentration was measured at a central laboratory using the Shinogi-32 human assay. A
single core laboratory reader interpreted all echocardiograms.
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Detailed anthropometric measurements (weight, height and head circumference) were made
at seven time points: study enrollment, 4 days after study enrollment, 2 weeks after
enrollment, pre-SCPC, 7 days after restarting study drug following SCPC, age 10 months,
and age 14 months. Study coordinators performing anthropometric measurements underwent
standardized training to ensure accurate and reliable measurements of weight and height
using training modules from the Health Resources and Service Administration Maternal and
Child Health Bureau (http://dept.washington.edu/growth/). Quality assurance measures
included the use of dedicated, appropriately calibrated scales, duplicate measurements, and
third measurements if the first two were not in agreement (within 0.1 kg for weight,
within1.0 cm for height). Measurements used in this analysis were limited to those
performed at PHN sites by trained study coordinators. All growth data were converted into
age-adjusted z-scores based on World Health Organization standards [14].
Statistical Analyses
Data are described as frequencies, medians with 25th and 75th percentile values, and means
with SD as appropriate. The study cohort used for analysis was restricted to those patients
with non-missing PDI and MDI scores. The data of subjects with missing MDI and PDI
scores (n=15, see details below) were compared with those with non-missing scores
(n=170). The variables listed in Appendix 2 were tested in a univariate manner for
association with PDI and MDI scores. Backward stepwise regression along with
bootstrapping to assess reliability of parameter estimates was used for selection of a final
multivariable model. The significance level for entry into the final multivariable model was
set at 0.05.
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In order to use longitudinal somatic measurements, such as weight, height, and head
circumference as predictors in regression analyses, we divided subjects into groups based on
individual trajectories. We used a semi-parametric, group-based approach to characterize
trajectories of weight, height, and head circumference z-scores. This approach, known as
group-based trajectory modeling (and based on the maximum-likelihood method) allows for
an easy identification of population heterogeneity both in terms of an attribute (e.g. height zscore) at a given age and how this attribute changes over time [18, 20–22]. This
methodology also has the advantage of handling missing data and allows the retention of
subjects with incomplete data during the course of the trial. Clustering of subjects into
groups based on individual trajectories allowed 1) simplification of regression modeling by
replacing seven correlated continuous predictors (e.g. height z-score from baseline until the
14-month visit) with one categorical cluster indicator and 2) assessment of clinically
relevant associations between growth trajectory profiles and neurodevelopmental outcomes.
Determining the appropriate number of clusters is a combination of science (the Bayesian
information criterion or BIC), and art (“whether the final model adequately addresses the
research question under investigation”). To determine the appropriate number of clusters, we
used the BIC as well as the variance in outcome (PDI and MDI scores) explained by the
cluster indicator. Although the association between a categorical cluster indicator (a
predictor) and PDI or MDI score (a one-dimensional dependent variable) was being
explored, a higher number of clusters did not necessarily improve the model. Some variables
such as serum BNP concentration and Ross heart failure classification were measured at two
study visits, pre-SCPC and at 14-months. The distribution of serum BNP concentration was
highly skewed and was normalized by logarithmic transformation (log BNP). For
multivariable modeling, log BNP was transformed into a categorical cluster indicator using
the group-based trajectory modeling approach described above. Dichotomous categorical
variables measured at 2 time points (pre-SCPC and at 14-months) were transformed into
categorical variables with 4 levels (Appendix 2).
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Results
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From August 2003 to May 2007, 230 infants with SV physiology were randomized, and 185
subjects were followed from study enrollment until the final study visit at the age of 14±1
months. Of these, 174 returned for BSID-II testing, however three test results were deemed
invalid following expert review (DCB), and one subject was excluded due to a missing MDI
score. Thus 170 subjects had valid PDI and MDI scores and constituted the study
population. Baseline characteristics of subjects with and without valid PDI and MDI scores
did not differ with the exception of the type of palliative surgery (P=.02) (Table I; available
at www.jpeds.com). For the 170 subjects, the median gestational age was 38 weeks, 9% of
patients had gestational age between 35–37 weeks, and 71% were males. Hypoplastic left
heart syndrome (HLHS) was the most common diagnosis (59%). The initial palliative
surgery was a Norwood procedure in 75%, a systemic-to-pulmonary artery shunt in 20%,
and a pulmonary artery band in 5%.
Mean PDI and MDI scores for all 170 subjects were 80.3±18.1 and 95.6±14.5 respectively,
both below the population mean of 100±15 (p<0.001 for both PDI and MDI). A PDI score <
85, which is 1 SD below the population mean, was seen in 58% of subjects, and 28% had a
PDI score < 70 (i.e. 2 SD below the population mean). A MDI score of < 85 was seen in
21% of subjects and 10% had a MDI score < 70.
Group-based trajectory analyses provided a two-group model (“high” and “low”) for height
z-score trajectory, and a three-group model (low, medium, and high) for weight and head
circumference z-score trajectories. The process is illustrated in the Figure, where height zscore trajectories for all subjects (panel A) were divided into “high” and “low” groups
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(panels B and C) with distinct mean values (panel D). With this method, 109 or 63% of
subjects were assigned to the “high” height z-score cluster, and 61 or 37% of subjects were
assigned to the “low” height z-score cluster. Of note, a majority of subjects in the “high”
cluster had higher height z-score at trial enrollment compared with those in the “low” cluster
(Figure, B and C). Overall subjects in the “high” group maintained higher height z-scores
throughout the study period compared with those in the “low” group, though there was some
overlap between the two groups.
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Similarly, group-based trajectory modeling provided a two-group model (“high” and “low”)
for log BNP trajectory. Using this method, 118 subjects were assigned to the “low” log BNP
cluster and 52 were assigned to the “high” log BNP cluster.
For PDI score, statistically significant relationships by univariate analysis were seen for the
following variables: HLHS diagnosis, hospital LOS and ECMO during neonatal
hospitalization, number of other cardiac procedures during SCPC hospitalization, Ross heart
failure class at 14 months, trajectories of height z-score, weight z-score, and head
circumference z-score, log BNP trajectory, and number of serious adverse events (SAE)
during the trial period (Table II).
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In the final multivariable model, height z-score trajectory was positively correlated with PDI
score with subjects in the “high” cluster scoring 15 points higher than those in the “low”
cluster (P<.001) (Table III). The total number of SAEs over the entire trial negatively
impacted PDI score; subjects experiencing fewer than two SAEs scored 10.6 points higher
than those with more than four SAEs (P=.02). Clinical site was also associated with PDI
scores (P=.02). This multivariable model explained 31% of the variance in PDI scores.
For MDI score, statistically significant relationships by univariate analysis were seen for the
following variables: Hispanic ethnicity, neonatal hospitalization outcomes including ECMO,
mode of feeding at discharge, use of supplemental oxygen at discharge, and LOS, presence
of moderate-to-severe atrioventricular valve regurgitation at 14 months, height z-score
trajectory, log BNP trajectory, total number of SAEs during the trial, and clinical site (Table
II).
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We also tested for an interaction between BNP and height by analyzing the relationship of
log BNP trajectory with MDI score in the “high” and “low” height z-score trajectories. In
the final multivariable model, subjects in the “low height trajectory- high log BNP
trajectory” scored on average 13–17 points lower than those in the other three groups (low
height-low BNP, high height-low BNP, high height-high BNP, P<.001; Table III). Mean
MDI score was 14 points lower in subjects requiring ECMO during the neonatal
hospitalization (P<.01), and 11 points lower in those discharged home on supplemental
oxygen after neonatal palliative surgery (p=0.01). Clinical site was also associated with MDI
scores (p<0.001). This multivariable model explained 36% of the variance in MDI scores.

Discussion
Severe stunting (height-for-age ≤ 2SD below normal) is an indicator of chronic malnutrition,
and is a major public health problem around the world. Children from developing countries
who are stunted in early childhood have poorer cognition, school achievement, and
psychosocial function in later childhood [23–24]. This study in the CHD population
demonstrates that lower height z-score trajectory in early infancy is associated with
neurodevelopmental disability.
Poor growth is a significant problem in infants with CHD, especially in those with SV
physiology prior to performance of the SCPC [14–16]. Infants with SV may experience
J Pediatr. Author manuscript; available in PMC 2014 February 01.
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feeding difficulties, gastro-esophageal reflux, uncharacterized genetic influences, alteration
in serum growth factors and growth hormone, and inadequate nutrition, which can impact
growth [25, 26]. In a retrospective study of 50 infants with HLHS, weight-forage z-score at
discharge was lower in children with longer hospital LOS, longer intensive care unit LOS,
shorter duration of parenteral nutrition and higher diuretic dosage at discharge [27].
Similarly, the ISV trial demonstrated that infants with SV physiology undergoing staged
reconstruction are “stunted” with both mean weight and height being below normal [14].
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Protein-energy malnutrition in fetal and early neonatal animal models results in a reduction
in brain size due to changes in structural proteins, growth factor concentrations, and
neurotransmitter production [28]. The rapid rate of brain growth along with the
developmental changes that occur during the third trimester of gestation and in the early
postnatal stage make it vulnerable to an inadequate diet. Smaller average head
circumferences and microcephaly have been reported in infants with HLHS [29]. This
suggests a disruption of normal fetal brain growth, which may increase the vulnerability of
the brain to poor nutrition in infants with HLHS.
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It is interesting to note that weight z-score trajectory did not have an impact on
neurodevelopment in multivariable analysis, even though it was associated with PDI score in
univariate analysis. This may be explained by the unexpected finding of greater impairment
of height rather than weight during the first 14 months in infants with SV physiology (14).
In a secondary analysis of data from the ISV study to determine factors that affect growth,
the mean change in weight z-score was −0.37±1.15 from enrollment to SCPC, and
+1.12±0.89 from SCPC to 14 months. Similarly height z-score decreased by −0.26 ± 1.16
from enrollment to SCPC, however there was a less dramatic improvement in height z-score
by +0.34±0.97 from the time of SCPC to 14 months [16]. Thus clinicians should be attentive
to poor linear growth in the first year of life as a marker for potential neurodevelopmental
abnormalities. Similarly, head circumference z-score trajectory was not independently
associated with neurodevelopmental outcome. With the SCPC, elevation of the intrathoracic central venous pressure is transmitted to the venous drainage of the brain, altering
cerebrospinal fluid re-absorption and increasing intracranial pressure at a time when the
skull is still quite malleable. This may represent pseudo-normalization of head
circumference measurements and alter the relationship between head circumference and
brain volume so that changes in head circumference do not necessarily reflect brain growth.
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Another unique finding of this study is the association of serum BNP concentration with
Neurodevelopmental outcome and the interaction between height trajectory and BNP
trajectory for MDI scores. Serum BNP is a surrogate marker of heart failure, and elevated
serum BNP concentration has been correlated with increased right and left sided intracardiac pressures [30–31]. Serum BNP concentration is expected to decline following the
volume unloading that occurs after the SCPC [13]. Persistent elevation of serum BNP
concentration at 14 months may be due to the presence of ventricular dysfunction and/or
atrioventricular valve regurgitation, each of which can cause heart failure. Subjects in the
“low height trajectory-high log BNP trajectory” had the lowest mean MDI scores. This
interaction suggests that subjects with persistent heart failure and lower height z-scores over
the first 14 months of life have worse neurodevelopmental outcome. This finding implies
that interventions to improve neurodevelopmental outcomes in infants with SV physiology
will need to include measures beyond improving nutritional status.
Consistent with previous studies, complications such as ECMO and a greater number of
SAEs during the trial were associated with worse BSID-II scores. This suggests that
hemodynamic instability and other morbidities both in the post-operative period, and after
hospital discharge affect neurodevelopmental outcomes. Lower systemic venous oxygen
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saturation suggestive of low cardiac output has been shown to negatively impact
neurodevelopment at 4.5 years [31]. Similarly longer hospital LOS, which is often a
surrogate for a complicated post-operative course, has also been associated with worse
outcome [32].
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Clinical site was also associated with BSID-II scores at 14 months. This could represent a
true difference between subjects due to unmeasured variation in patient characteristics or
management strategies across sites. Alternatively, differences in ascertainment of
neurodevelopmental status may be due to variation in testing by the site psychologist.
Although psychologists at all sites were certified by a PHN expert, the difference may also
be related to subjective differences in scoring by the designated site psychologists. It is
interesting to note that, contrary to other studies, factors such as socioeconomic status,
diagnosis of HLHS, or the Norwood procedure as neonatal palliative surgery were not
associated with neurodevelopmental outcomes in our cohort (34, 35).
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This study has some important limitations. Only subjects less than 45 days of age who were
well with stable systemic and pulmonary blood flow were approached for enrollment. Sicker
subjects who may be at the highest risk for worse neurodevelopmental outcome were not
included in this study. Subjects with recognizable genetic or phenotypic syndromes were
excluded from the ISV trial. However most subjects did not undergo formal genetic
evaluation and unrecognized genetic abnormalities may have been present in our study
cohort. Another limitation of this study is the lack of information about nutritional intake.
The study protocol did not include assessment of nutritional intake at discharge from
neonatal hospitalization. Although the protocol included collection of data on caloric intake
during the seven study visits, this information was incomplete and not obtained consistently.
The study was also limited by lack of formal neurologic evaluation or neuroimaging. The
predictive value of neurodevelopmental testing at the age of14 months is limited. The BSIDII provides a good assessment of developmental strengths and weaknesses. However, it is
not an intelligence test and assessment of one-year mental and motor development may
correlate only modestly with performance later in life [36]. Our study design allowed us to
identify factors associated with worse neurodevelopmental outcome, but not to determine
causality.
Clinical efforts should be directed at improving nutritional status and decreasing heart
failure in infants with single ventricle physiology.
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Appendix

Pediatric Heart Network Investigators include:
National Heart, Lung, and Blood Institute: Gail Pearson, Victoria Pemberton, Mario
Stylianou, Marsha Mathis
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Network Chair: Lynn Mahony, University of Texas Southwestern Medical Center
Data Coordinating Center: New England Research Institutes, Lynn Sleeper (PI), Steven
Colan, Lisa Virzi, Lisa Wruck*, Victor Zak, David F. Teitel
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Core Clinical Site Investigators: Children’s Hospital Boston, Jane W. Newburger (PI),
Roger Breitbart, Jami Levine, Ellen McGrath, Carolyn Dunbar-Masterson; Children’s
Hospital of New York, Daphne Hsu* (Study Chair), William Hellenbrand (PI), Ashwin
Prakash*, Seema Mital*, Darlene Servedio*; Children’s Hospital of Philadelphia, Victoria
L. Vetter (PI), Chitra Ravishankar, Sarah Tabbutt*, Meryl Cohen, Katherine Lee, Marisa
Nolan, Stephanie Piacentino, Michelle Toms; Cincinnati Children’s Medical Center, D.
Woodrow Benson (PI), Catherine Dent Krawczeski, Lois Bogenschutz, Teresa Barnard,
Steven Schwartz*, David Nelson; North Carolina Consortium: Duke University, East
Carolina University, Wake Forest University, Page A. W. Anderson (PI) – deceased,
Jennifer Li (PI), Wesley Covitz, Kari Crawford, Michael Hines, James Jaggers, Theodore
Koutlas, Charlie Sang, Jr, Lori Jo Sutton, Mingfen Xu; Medical University of South
Carolina, J. Philip Saul (PI), Andrew Atz, Girish Shirali, Eric M. Graham, Teresa Atz;
Primary Children’s Medical Center and the University of Utah, Salt Lake City, Utah, L.
LuAnn Minich (PI), John A. Hawkins, Richard V. Williams, Linda M. Lambert, Marian E.
Shearrow; Hospital for Sick Children, Toronto, Brian McCrindle (PI), Elizabeth
Radojewski, Nancy Slater, Svetlana Khaikin, Susan McIntyre.
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Auxiliary Sites: Children’s Hospital of Wisconsin, Nancy Ghanayem, Kathy Mussatto,
Michele Frommelt, Lisa Young-Borkowski; University of Michigan, Albert Rocchini,
Laurie Rodgers-Augustyniak
Echocardiography Core Laboratory: Children’s Hospital Boston: Steven Colan, Renee
Margossian
Genetics Core Laboratory: Children’s Hospital of New York: Wendy Chung, Liyong Deng,
Patricia Lanzano
Protocol Review Committee: Michael Artman, Chair; Judith Massicot-Fisher, Executive
Secretary; Timothy Feltes, Julie Johnson, Thomas Klitzner, Jeffrey Krischer, G. Paul
Matherne
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Data and Safety Monitoring Board: John Kugler, Chair; Rae-Ellen Kavey, Executive
Secretary; David J. Driscoll, Mark Galantowicz, Sally A. Hunsberger, Thomas J. Knight,
Holly Taylor, Catherine L. Webb
*no longer at the institution listed

Appendix 2
Patient factors (8 variables)
Gestational age (weeks)
Race
Sex
Ethnicity
Anatomic Diagnosis (Hypoplastic left heart syndrome/HLHS – yes/no)
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Household income (annual, Socioeconomic status/SES)
Highest grade of school completed by parent/guardian filling the questionnaire (SES)
Ventricular type (Left vs. Right/Mixed)
Feeding regimen (1 variable)
Feeding mechanism* (Tube/Bottle/Breast) – at the time of discharge after neonatal surgery
Factors during neonatal hospitalization (9 variables)
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Age at palliative surgery (days)
Type of palliative surgery (Norwood –yes/no) (‘no’ includes 5 patients without neonatal
surgery)
Total bypass time (minutes)
Aortic cross clamp time (minutes)
Circulatory arrest (yes/no)
Concurrent procedures (number of) (transformed to dichotomous: 0 or > 0)
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Length of hospital stay (for neonatal surgery, days) (transformed to quartiles)
Total time on ventilator following neonatal surgery (days, transformed to quartiles)
Supplemental oxygen at discharge (yes/no)
Factors during SCPC hospitalization (3 variables)
Age at SCPC surgery (days)
Concurrent cardiac surgical procedures (number of) (transformed to dichotomous: 0 or > 0)
Length of hospital stay (days) (transformed to quartiles)

$watermark-text

ECHO (4 variables)
Overall Atrioventricular/AV valve regurgitation (None/Mild vs. Moderate/Severe)* at preSCPC and 14-month visits
Systemic Ventricular Dysfunction (None vs. Mild/Moderate/Severe) at baseline
BNP (5 variables)
Logarithm of BNP at pre-SCPC and 14-month visits
Dichotomous variable BNP <100 pg/ml (Yes/No)* at pre-SCPC and 14-month visits
ROSS (3 variables)
Ross heart classification (class 1 vs. classes 2–4)* at pre-SCPC and 14-month visits
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*In addition to dichotomous (Yes/No) variables at pre-SCPC and 14-month visits we created
a variable with 4 levels (YY, YN, NY, NN) accounting for both visits and used this variable
in multivariate modeling.
RAAS gene polymorphism (1 variable)
High risk (Yes/No) (high risk genotype (homozygous) present in at least 2 genes out of five
vs. in only one gene, or absent)
GROWTH (22 continuous variables, converted into 3 categorical)

$watermark-text

Growth z-scores (weight, height and head circumference) at randomization, 4 days, two
weeks, pre-Glenn, 7days after restarting study drug, 10 month and14 month visits. Birth
weight z-score
ADVERSE EVENTS (AE) (over the duration of the trial, 3 variables)
Total number of serious AE (varies from 0 to17: a categorical form will be used: <2, 2–4,
>4)
Neurological SAE (yes/no) (only 10 subjects have neurological SAE, each has 1)
ECMO (yes/no) (only 6 subjects have ECMO, one of them twice)
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SITE (1 variable)

$watermark-text
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Figure.

Trajectories of height z-scores over time for 170 subjects with PDI and MDI scores (7
visits): Individual trajectories for A, all subjects, B, 109 subjects in the “high” cluster, and
C, 61 subjects in the ‘low’ cluster. D, Mean values by visit for each cluster.
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Table 1

Baseline characteristic comparing 170 subjects with valid PDI and MDI scores and those without valid scores

$watermark-text

Characteristic

Valid PDI and MDI score

No valid PDI and MDI score

170

15

Mean Age at Enrollment, Days

21.0 ± 9.3

22.5 ± 10.4

0.56

Median Age at Enrollment, Days

19 (14, 27)

22 (13, 35)

0.59

71%

73%

1.00

N

Male

p-value

0.07

Race
White

81%

80%

Black or African American

15%

7%

Asian

1%

13%

4%

0%

Other

$watermark-text

Hispanic
Median Gestational Age, Weeks (imputed)*
Gestational age < 37 weeks

14%

20%

0.47

38 (37, 39)

39 (37, 40)

0.53

9%

7%

1.00

Mean Weight, kg

3.38 ± 0.55

3.22 ± 0.49

0.27

Weight-for-Age Z-score-WHO

−1.28±1.31

−1.71±1.26 (15)

0.22

Mean height, cm

51.1 ± 2.4

50.6 ± 2.1

0.40

Height-for-Age Z-score-WHO

−1.06±1.31

−1.45±1.10 (15)

0.27

34.3±1.6

34.1±1.3 (15)

0.56

−1.72±1.44

−2.02±1.17 (15)

0.43

Single Ventricle

32%

20%

Hypoplastic Left Heart Syndrome

59%

73%

Other Functional Single Ventricle

9%

7%

Unclassified

1%

0%

Mean Head Circumference, cm
Head Circumference Z-score-WHO (n=169)

0.68

Single Ventricle Anatomic Diagnosis

$watermark-text

Type of Surgery

0.02

Norwood

72%

73%

Systemic-to-Pulmonary Shunt

20%

0%

PA Band

5%

13%

Damus-Kaye-Stansel

2%

13%

None/Mild

78%

67%

Moderate/Severe

23%

33%

0.35

Overall AV valve regurgitation-dichotomous

0.59

Systemic Ventricular Dysfunction
None

83%

79%

Mild

12%

14%

Moderate

5%

7%

Severe

0%

0%

Enalapril

51%

27%

Placebo

49%

73%

0.10

Treatment Arm (ITT)
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*

Gestational age imputed as 40 weeks for 2 full-term patients, WHO-World Health Organization, PA-pulmonary artery, AV-atrioventricular, ITTintention to treat.
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44
69

medium

low

Log BNP trajectories

57

high

170

52

low
170

80

medium

Head Circumference trajectories

38

high

170

61

Weight trajectories

109

142

150

low

170

166

13
32.2±25.8

high

Height trajectories

Growth trajectories cluster indicator

AVVR ┼ (None/Mild)

14 month visit

No other procedures at SCPC

169

170

Pre-SCPC visit

170

6

Breast

Length of stay (days)

81

Bottle

Supplemental oxygen at discharge

83

100

24

Value

Tube

Feeding Mechanism at discharge

170

170

HLHS

Neonatal hospitalization

167

N*

Hispanic origin

Patient factors

Variable

1.9

0.0

11.9

−9.6

0.0

4.7

0.0

15.8

2.2

11.6

−0.2

4.8

−1.2

3.4

0.0

−3.5

−3.9

PDI

0.9

0.0

4.9

−4.9

0.0

0.6

0.0

8.9

5.5

6.7

−0.1

3.0

−6.1

5.0

0.0

−2.8

−7.0

MDI

Parameter Estimate**

0.01

0.009

0.02

<0.001

0.37

0.006

0.002

0.25

0.74

0.03

0.32

PDI

0.004

0.12

0.09

<0.001

0.02

0.01

0.01

0.01

0.04

0.17

0.05

MDI

p-value** (site-adjusted)
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Variables significantly associated with PDI and MDI scores by univariate analysis
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36
6

170
170
170

Low-Low

ECMO (neonatal surgery):

Total number of serious adverse events

Total number of serious adverse events

12

>4
-

0.0

6.9

14.8

−1.9

−19.0

NA

NA

N/A

N/A

-

0.0

10.1

14.8

−2.2

−15.0

0.0

−14.4

2.68

3.96

0.0

−6.7

MDI

0.07

0.001

<.001

0.04

N/A

PDI

0.05

0.011

<.001

0.01

0.006

MDI

p-value** (site-adjusted)

parameter estimate represents change in the dependent variable associated with a one integer unit change in the explanatory variable, HLHS-hypoplastic left heart syndrome, min-minutes, BNP-brain type
natriuretic peptide, AVVR-atrioventricular valve regurgitation, SCPC-superior cavopulmonary connection, ECMO-extracorporeal membrane oxygenation, NA-not applicable.

From linear regression modeling

**

N/A

61

2–4

Clinical site

97

<2

total number of subjects with a measurement

*

25

Low-High

170

82

1.8±2.2

27

0.0

118

High-Low

170

−9.4

PDI

Parameter Estimate**

52

High-High

Height and Log BNP trajectories cluster indicator interaction

low

high

$watermark-text
Value
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N*
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Variable
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reference

>4

−12.79
reference

Low--High

Low-Low

on a subset of 6 key variables with bootstrapping reliability above 30% and univariate p-values under 0.2

57.7

75.3

56.6

48.2

94.7

0.05

<0.001

0.01

0.01

0.001

P
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High and low are labels for two levels of the trajectories cluster indicator

§

On a subset of 9 key variables with bootstrapping reliability above 30% and univariate p-values under 0.2, SAEs-serious adverse events, ECMO-extracorporeal membrane oxygenation, BNP-brain type
natriuretic peptide

**

*

PDI: N=170, R2 = 0.31, R2 adjusted = 0.30, MDI: N=167, R2 = 0.36, R2 adjusted = 0.33

−5.58

4.58

High-Low§

Hispanic

4.45

High§-High

Height and Log BNP trajectories cluster indicator interaction

−11.00

-

Supplemental Oxygen (after neonatal surgery)

0.02

0.02

<0.001

−13.30

85.5

56.2

100

Bootstrapping Reliability**, %

Estimate

Bootstrapping Reliability*, %
P

MDI

PDI

ECMO

Site

3.81

10.61

14.99

Estimate

2–4

<2

Total Number of SAEs

Height trajectories cluster indicator, High vs. Low

Variable
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Final multivariable models for PDI and MDI scores at 14 months
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